9 results
Primary: To estimate the antitumor activity (assessed as overall response rate) of PDR001 as a single agent in patients with non-functional neuro-endocrine tumors (NET).Secondary: To estimate efficacy (duration of response) of PDR001. Safety and…
The objective is to investigate the effectiveness of an Internet-based self-help intervention for people with mild symptoms of anxiety and/or depression. This intervention will be offered with and without guidance and will be compared to usual care…
Primary Objective:* The primary objective is to demonstrate the efficacy of avapritinib based on progression-free survival (PFS) determined by central radiological assessment per modified Response Evaluation Criteria in Solid Tumors (mRECIST),…
Objective: To investigate the feasibility and acceptability of the online cognitive behavioral therapy program (eHealth CF-CGT), so that the program can be tailored to the needs of the patient
Primary: Part 1 • To determine the RP2D of avapritinib in patients with ISM for use in Part 2 and Part 3 of the study.Part 2 • To determine main change in ISM-SAF TSS from baseline to C7D1, compared to placebo. Part 3 • To assess the long-term…
* Safety Run inTo determine the recommended regimen of PDR001 in combination with dabrafenib and trametinib for the randomized part (part 3)* Biomarker cohortTo evaluate changes in the immune microenvironment and biomarker modulations upon treatment…
To investigate the efficacy of bCBT compared to usual care in severely fatigued patients with primary brain tumors.
Primary: • The primary objective is to determine adjudicated ORR (CR/CR with partial recovery of peripheral blood counts [CRh] + PR + CI) based on modified IWG-MRT-ECNM consensus response criteria in patients with AdvSM treated with avapritinib and…
The aims of this project are to 1) to determine the non-inferiority of inter-CBT, compared to a benchmark study where CBT was provided by psychologists (TIRED study), in its effect on reduction in cancer-related fatigue, 2) to adapt CBT delivery to…